Aaron Edwards

CEO + Co-Founder at KiraGen Bio

Speaker

Aaron Edwards is Co-Founder & CEO of KiraGen Bio, a Cambridge-based biotech engineering multiplex-edited CAR-T therapies to overcome the suppressive tumor microenvironment in solid tumors. Prior to founding KiraGen, he led in vitro biology for Beam Therapeutics’ BEAM-201, the first quadruple base-edited CAR-T to reach the clinic, and earlier worked on gene editing applications for CAR-T and TCR-T therapies at Bluebird Bio. Aaron holds an MS/MBA in Biotechnology from Harvard Business School and the Graduate School of Arts & Sciences and an MS in Medical Sciences from Boston University. He is a Henri Termeer Fellow and Blavatnik Fellow in Life Science Entrepreneurship. At KiraGen, Aaron oversees fundraising, partnerships, and overall company strategy while guiding the advancement of KiraLOGIC, the company’s AI-driven platform for rational multiplex editing. The company’s lead program is a dual-targeting, 6KO CAR-T for glioblastoma, with a broader focus on models that enable advanced therapies to reach rare disease populations.